WO2003043613A3 - Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents - Google Patents

Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents Download PDF

Info

Publication number
WO2003043613A3
WO2003043613A3 PCT/DK2002/000783 DK0200783W WO03043613A3 WO 2003043613 A3 WO2003043613 A3 WO 2003043613A3 DK 0200783 W DK0200783 W DK 0200783W WO 03043613 A3 WO03043613 A3 WO 03043613A3
Authority
WO
WIPO (PCT)
Prior art keywords
diacylglycerol
glycosides
mono
inflammatory agents
octadeca
Prior art date
Application number
PCT/DK2002/000783
Other languages
French (fr)
Other versions
WO2003043613A2 (en
Inventor
Erik Larsen
Arsalan Kharazmi
Soeren Broegger Christensen
Lars Porskjaer Christensen
Kirsten Brandt
Original Assignee
Danmarks Jordbrugsforskning
H S Rigshospitalet
Danmarks Farmaceutiske Hoejsko
Erik Larsen
Arsalan Kharazmi
Soeren Broegger Christensen
Lars Porskjaer Christensen
Kirsten Brandt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danmarks Jordbrugsforskning, H S Rigshospitalet, Danmarks Farmaceutiske Hoejsko, Erik Larsen, Arsalan Kharazmi, Soeren Broegger Christensen, Lars Porskjaer Christensen, Kirsten Brandt filed Critical Danmarks Jordbrugsforskning
Priority to AU2002366210A priority Critical patent/AU2002366210A1/en
Priority to JP2003545294A priority patent/JP4716655B2/en
Priority to DK02803339.7T priority patent/DK1453844T3/en
Priority to EP02803339.7A priority patent/EP1453844B1/en
Publication of WO2003043613A2 publication Critical patent/WO2003043613A2/en
Publication of WO2003043613A3 publication Critical patent/WO2003043613A3/en
Priority to NO20042112A priority patent/NO334587B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)

Abstract

Glycosides of diacylglycerol, e.g. 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO) (A), which was isolated from extracts of rose-hips by activity guided fractionation, can be used as an oral anti-inflammatory agent for the treatment of inflammatory diseases such as arthritis and osteoarthrosis.
PCT/DK2002/000783 2001-11-21 2002-11-21 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents WO2003043613A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002366210A AU2002366210A1 (en) 2001-11-21 2002-11-21 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
JP2003545294A JP4716655B2 (en) 2001-11-21 2002-11-21 Use of mono- and diacylglycerol glycosides as anti-inflammatory agents
DK02803339.7T DK1453844T3 (en) 2001-11-21 2002-11-21 APPLICATION OF GLYCOSIDES OF MONO- AND DIACYLGYLCEROL AS ANTI-INFLAMMATORY AGENTS
EP02803339.7A EP1453844B1 (en) 2001-11-21 2002-11-21 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
NO20042112A NO334587B1 (en) 2001-11-21 2004-05-21 Use of glycosides of diacylglycerol as anti-inflammatory agents.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33208401P 2001-11-21 2001-11-21
US60/332,084 2001-11-21
US34160901P 2001-12-18 2001-12-18
US60/341,609 2001-12-18
US35839102P 2002-02-22 2002-02-22
US60/358,391 2002-02-22

Publications (2)

Publication Number Publication Date
WO2003043613A2 WO2003043613A2 (en) 2003-05-30
WO2003043613A3 true WO2003043613A3 (en) 2004-03-25

Family

ID=27406836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000783 WO2003043613A2 (en) 2001-11-21 2002-11-21 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents

Country Status (9)

Country Link
US (2) US7084122B2 (en)
EP (1) EP1453844B1 (en)
JP (2) JP4716655B2 (en)
CN (1) CN100469784C (en)
AU (1) AU2002366210A1 (en)
DK (1) DK1453844T3 (en)
NO (1) NO334587B1 (en)
PL (2) PL213644B1 (en)
WO (1) WO2003043613A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
AR035700A1 (en) * 2001-05-08 2004-06-23 Astrazeneca Ab DERIVATIVES OF ARILHETEROALQUILAMINA, PHARMACEUTICAL COMPOSITION, USES OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, AND PROCESS FOR THE PREPARATION OF THESE DERIVATIVES
SE0102640D0 (en) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0203304D0 (en) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
JP3914519B2 (en) * 2003-06-06 2007-05-16 株式会社スピルリナ研究所 Lipase activity inhibitor comprising a glyceroglycolipid compound
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
CN102309573B (en) * 2003-09-12 2013-11-20 捷通国际有限公司 Cytokine modulators and related method of use
JP3790767B2 (en) * 2004-06-30 2006-06-28 森下仁丹株式会社 Fat metabolism improving composition
US20070269540A1 (en) * 2006-05-16 2007-11-22 Morishita Jintan Co., Ltd. Fat metabolism improving agent
JP4866067B2 (en) * 2005-11-22 2012-02-01 株式会社ファンケル Melanin production inhibitor
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
JP2009541371A (en) * 2006-07-03 2009-11-26 ヒーベン・ビタル・ライセンス・アンパルトセルスカブ Process for the production of mono- or diacylglycerol product glycosides from plant material
US7547455B2 (en) * 2006-09-20 2009-06-16 Academia Sinica Cancer and inflammatory disorder treatment
KR100772078B1 (en) 2006-11-07 2007-10-31 한국기초과학지원연구원 Novel monogalactosyldiacylglycerol compounds isolated from sargassum thunbergii
JPWO2008108001A1 (en) * 2007-03-02 2010-06-10 株式会社東洋新薬 Galactolipid
MX2010006955A (en) 2007-12-21 2010-12-14 Finzelberg Gmbh & Co Kg Preparations with rosehip extracts, and method of producing rosehip extracts.
NZ567712A (en) * 2008-04-24 2010-11-26 Fonterra Cooperative Group Ltd Compositions and methods for maintaining bone health or reducing bone loss
US9173912B2 (en) 2008-05-06 2015-11-03 Finzelberg Gmbh & Co. Kg Cistus extract containing enriched secondary plant ingredients
WO2010048955A1 (en) 2008-10-30 2010-05-06 Hyben Vital Licens Aps Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition
DK177605B1 (en) 2010-03-16 2013-11-18 Hyben Vital Licens Aps Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis
EP2389816A1 (en) 2010-05-25 2011-11-30 Nestec S.A. Synergistic antioxidant composition
JP5819951B2 (en) * 2010-06-25 2015-11-24 ホーファグ リサーチ （アイピー） ピーアールイー リミテッド Composition for improving sexual wellness
TWI558403B (en) * 2013-06-04 2016-11-21 中央研究院 Galactolipids-enriched plant extracts and the uses thereof
JP6339426B2 (en) * 2014-06-30 2018-06-06 株式会社ファンケル Method for producing composition containing glyceroglycolipid and glyceroglycolipid-containing composition
AU2017289278A1 (en) 2016-06-27 2019-01-17 Ohio State Innovation Foundation Liponucleotide-based therapy for ARDS
CN106983763B (en) * 2017-04-25 2021-04-20 中国海洋大学 Monogalactosyl diacyl glyceride and preparation method and application thereof
CN110201026B (en) * 2019-07-15 2021-09-24 青岛农业大学 Non-antibiotic colitis repairing preparation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271270A (en) * 1992-03-27 1993-10-19 Nippon Paper Ind Co Ltd Sugar-glycerol derivative and its synthesis
JPH06336437A (en) * 1993-03-30 1994-12-06 Takeda Shokuhin Kogyo Kk Carcinogenic promotion-inhibiting composition
JPH07149786A (en) * 1993-11-26 1995-06-13 Sagami Chem Res Center Glyceroglycolipid and carcinogenic promoter inhibitor
EP0671406A2 (en) * 1994-03-04 1995-09-13 Bristol-Myers Squibb Company Sulfated beta-glycolipid derivatives as cell adhesion inhibitors
EP0671407A2 (en) * 1994-03-04 1995-09-13 Bristol-Myers Squibb Company Sulfated alpha-glycolipid derivatives as cell adhesion inhibitors
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
DE19634019A1 (en) * 1996-08-23 1998-02-26 Beiersdorf Ag Antimicrobial, antiviral, antiparasitic and antiprotozoal agents
DE19634021A1 (en) * 1996-08-23 1998-02-26 Beiersdorf Ag Microbial adhesion inhibitor comprising glyco:glycero:lipid
WO1998030573A1 (en) * 1997-01-13 1998-07-16 Glycorex Ab Anti-adhesive sulfatide analogues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024984A2 (en) 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
US6024960A (en) * 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271270A (en) * 1992-03-27 1993-10-19 Nippon Paper Ind Co Ltd Sugar-glycerol derivative and its synthesis
JPH06336437A (en) * 1993-03-30 1994-12-06 Takeda Shokuhin Kogyo Kk Carcinogenic promotion-inhibiting composition
JPH07149786A (en) * 1993-11-26 1995-06-13 Sagami Chem Res Center Glyceroglycolipid and carcinogenic promoter inhibitor
EP0671406A2 (en) * 1994-03-04 1995-09-13 Bristol-Myers Squibb Company Sulfated beta-glycolipid derivatives as cell adhesion inhibitors
EP0671407A2 (en) * 1994-03-04 1995-09-13 Bristol-Myers Squibb Company Sulfated alpha-glycolipid derivatives as cell adhesion inhibitors
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
DE19634019A1 (en) * 1996-08-23 1998-02-26 Beiersdorf Ag Antimicrobial, antiviral, antiparasitic and antiprotozoal agents
DE19634021A1 (en) * 1996-08-23 1998-02-26 Beiersdorf Ag Microbial adhesion inhibitor comprising glyco:glycero:lipid
WO1998030573A1 (en) * 1997-01-13 1998-07-16 Glycorex Ab Anti-adhesive sulfatide analogues

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AKIRA MURAKAMI ET AL: "Glyceroglycolipids from Citrus hystrix, a Traditional Herb in Thailand, Potently Inhibit the Tumor-Promoting Activity of 12-=-Tetradecanoylphorbol 13-Acetate i Mouse Skin", J. AGRIC. FOOD CHEM., vol. 43, 1995, pages 2779 - 2783, XP002237422 *
ARSALAN KHARAZMI ET AL: "Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain infalmmatory parameters in vivo", INFLAMMOPHARMACOLOGY, vol. 7, no. 4, 1999, pages 377 - 386, XP002237424 *
CATENI F. ET AL: "Biologically active compounds from Euphorbiaceae; three new glycolipids with anti-inflammatory activity from Euphorbia cyparissias L.", PHARM PHARMACOL LETT, vol. 2, 2001, pages 53 - 57, XP002237420 *
DATABASE STN CAPLUS RN 310878-75-2; XP002237421 *
HIROTAKA SHIBUYA ET AL: "Synthesis of a Glycerophospholipid, C16-Platelet Activating Factor and a Palmitoyl Analogue of M-5, an Anti-inflammatory Glyceroglycolipid", CHEM. PHARM. BULL., vol. 40, no. 5, 1992, pages 1166 - 1169, XP002237419 *
HIROYUKI KIKUCHI ET AL: "Marine Natural Products. XI. An Antiinflammatory Scalarane-type Bishomosesterterpene, Foliaspongin, from the Okinawan Marine Sponge Phyllospongia foliascens (PALLAS)", CHEM. PHARM. BULL., vol. 31, no. 2, 1983, pages 552 - 556, XP002237423 *
K. WINTHER ET AL: "The anti-inflammatory properties of rose-hip", INFLAMMOPHARMACOLOGY, vol. 7, no. 1, 1999, pages 63 - 68, XP002237425 *
KIM, CHUL YOUNG ET AL: "Galactolipids from Mori Folium and their Hypoglycemic effect", SAENGYAK HAKHOECHI, vol. 31, no. 1, 2000, pages 95 - 100 *
NAOKI OHTA ET AL: "Synthesis of Biologically Active Galactosyl and Glucosyl-Glycerol Derivatives", CHEM. PHARM. BULL., vol. 39, no. 5, 1991, pages 1337 - 1339, XP002237418 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 046 (C - 1157) 25 January 1994 (1994-01-25) *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 03 28 April 1995 (1995-04-28) *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 09 31 October 1995 (1995-10-31) *

Also Published As

Publication number Publication date
PL370888A1 (en) 2005-05-30
NO334587B1 (en) 2014-04-14
JP2010215660A (en) 2010-09-30
PL393941A1 (en) 2011-06-20
EP1453844A2 (en) 2004-09-08
WO2003043613A2 (en) 2003-05-30
AU2002366210A1 (en) 2003-06-10
US20050049205A1 (en) 2005-03-03
CN100469784C (en) 2009-03-18
AU2002366210A8 (en) 2003-06-10
US20030139350A1 (en) 2003-07-24
NO20042112L (en) 2004-07-09
PL213644B1 (en) 2013-04-30
JP2005513023A (en) 2005-05-12
US7084122B2 (en) 2006-08-01
CN1606563A (en) 2005-04-13
EP1453844B1 (en) 2013-11-20
DK1453844T3 (en) 2014-02-10
JP4716655B2 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
WO2003043613A3 (en) Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
WO2002053519A3 (en) Hydrophobic polyamine analogs and methods for their use
EE200200632A (en) Preparations containing glucocorticoids for the treatment of bronchopulmonary disorders
WO2004016640A3 (en) 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2002221276A1 (en) Insulator of particles created between the articulating components of artificialjoints
WO2002095420A3 (en) Process connection
WO2001097771A3 (en) Preparations that contain an extract of the plant pistia stratiotes
AU2002330245A1 (en) Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use
AU2002240835A1 (en) Process for the manufacture of solid formulations
AU2002250855A1 (en) Polymer-stabilized aqueous mixtures of plant protective agents
AU2002353315A1 (en) Disruption of the phosphodiesterase 10 gene
AU2002357964A1 (en) Use of coagulant-active antitrhombin iii for the therapy of angiogenesis-dependent diseases
AU2002352424A1 (en) Solution-phase process for the manufacture of decapeptide
IT1318676B1 (en) PROCESS AND MIXTURE FOR THE PREPARATION OF METALLIC SULPHURS.
AU2002323167A1 (en) Substituted 7-aza(2.2.1) bicycloheptanes for the treatment of diseases
AU2002303821A1 (en) Aryl-8-azabicyclo(3.2.1)octanes for the treatment of depression
AU2002229479B2 (en) Preparation for the prophylaxis of restenosis
GB0115361D0 (en) Process for the manufacture of solid formulations
AU2002347884A1 (en) Compositions and methods for the therapy and diagnosis of acne vulgaris
AU2002313019A1 (en) Compounds of the family of 3-alkyl-(4,5 dipheny-imidazol-1-yl) and their use as soothing agents
AUPR532801A0 (en) Conrod guidance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003545294

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002803339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028258169

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002803339

Country of ref document: EP